Adavosertib for Cancer

Recruiting in Palo Alto (17 mi)

+28 other locations

Overseen byRahul R Aggarwal

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: National Cancer Institute (NCI)

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This trial studies how well adavosertib works in patients with advanced or metastatic solid tumors that lack the SETD2 gene. Adavosertib may help stop tumor growth by blocking enzymes needed for cancer cells to grow. Adavosertib is a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, previously shown to have clinical activity in various cancers.

Eligibility Criteria

This trial is for adults with advanced solid tumors that have spread and have a SETD2 mutation. They must have tried at least one therapy, be able to swallow pills, not be pregnant or breastfeeding, use contraception if fertile, and meet certain health criteria like specific blood cell counts.

Inclusion Criteria

I am a male willing to use condoms during the study and for 3 months after it ends.

Your liver enzymes (AST and ALT) are not more than three times the normal levels, or not more than five times the normal levels if you have liver metastases.

I have advanced kidney cancer with a specific genetic change and have had previous treatment.

+13 more

Exclusion Criteria

I am not on any cancer treatments except possibly LHRH analogues for over 6 months.

I haven't had major surgery in the last 28 days or minor surgery in the last 7 days.

I do not have active brain cancer or symptoms from previous brain metastases.

+10 more

Participant Groups

The trial is testing Adavosertib's effectiveness on patients with SETD2-deficient advanced solid tumors. It's a phase II study where the drug aims to block enzymes needed for tumor growth.

1Treatment groups

Experimental Treatment

Group I: Treatment (adavosertib)Experimental Treatment1 Intervention

Patients receive adavosertib PO QD on days 1-5 and 8-12. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.